Free Trial
NASDAQ:DXCM

DexCom Q2 2025 Earnings Report

DexCom logo
$88.99 +2.25 (+2.59%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$88.70 -0.30 (-0.33%)
As of 07/25/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom EPS Results

Actual EPS
N/A
Consensus EPS
$0.45
Beat/Miss
N/A
One Year Ago EPS
N/A

DexCom Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.13 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

DexCom Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, July 30, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

DexCom Earnings Headlines

I’d rather trade news like this than gamble on hype
Real traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal just triggered a key alert in Tim Sykes’ system… and the setup looks strong.
DexCom: Delivering Consistent Growth
DexCom (NASDAQ:DXCM) Rating Increased to Buy at Wall Street Zen
See More DexCom Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DexCom? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DexCom and other key companies, straight to your email.

About DexCom

DexCom (NASDAQ:DXCM), a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

View DexCom Profile

More Earnings Resources from MarketBeat